Key result
Dynamic IL-6 and HSP monitoring predicts post-PCI major cardiovascular events in STEMI with ~0.88 AUC, beating GRACE.
Why the study?
In post-PCI STEMI patients, an imbalance between inflammation and cellular protection drives poor prognosis, and risk assessment systems relying on static markers fail to meet clinical needs.
Does dynamic monitoring of IL-6, HSP22, and HSP27 predict post-PCI MACE in STEMI patients?
Cohort (n=266)
No
Does dynamic monitoring of IL-6, HSP22, and HSP27 predict post-PCI MACE in STEMI patients?
Dynamic monitoring of IL-6 and HSP22/HSP27 provides synergistic predictive value for MACE after PCI in STEMI patients.
Answers are grounded in this paper and cite their sources.
May support combined IL-6/HSP22/27 monitoring for post-PCI MACE risk in STEMI; hypothesis-generating and requires prospective validation.
BACKGROUND: In patients with STEMI after PCI, an imbalance between the inflammatory response and cellular protective mechanisms is a key factor leading to poor prognosis. The current risk assessment system, which is based on static markers, fails to meet clinical needs. This study aimed to determine a novel dynamic monitoring model that jointly detects the pro-inflammatory cytokine IL-6 and the stress-response proteins HSP22 and HSP27 to optimize risk stratification and prognosis prediction for STEMI patients. METHODS: A prospective cohort study design was employed; 176 patients with STEMI and 90 patients with SCHD who underwent emergency PCI from June 2023 and January 2025 were consecutively enrolled. Serum levels of IL-6, HSP22, and HSP27 were measured at baseline and during the periprocedural period (preprocedure, 1/3/4 days postprocedure), and MACE were monitored for 6 months. OBJECTIVE: The predictive efficacy of each marker was evaluated through ROC curve and logistic regression analyses, and a dynamic risk scoring model was established. RESULTS: The baseline levels of IL-6 (7.01 ± 2.87 vs. 2.91 ± 1.17 pg/mL), HSP22 (0.591 vs. 0.365 ng/mL), and HSP27 (1.828 vs. 1.090 ng/mL) in the STEMI group were significantly greater than those in the control group (all P < 0.001). The AUCs of each marker for STEMI diagnosis were > 0.9, with HSP27 being the best (AUC = 0.972). Dynamic monitoring revealed characteristic temporal changes: the IL-6 level peaked on the first day after PCI (AUC = 0.785), and the HSP22/HSP27 level peaked on the third day after PCI (AUC = 0.793/0.794). The combined prediction of MACEs by the three markers reached an AUC of 0.875 (sensitivity 70.0%, specificity95.9%), and all were independent predictors. CONCLUSION: This study confirms that the divergent temporal profiles of IL-6 (the first day after PCI) and HSP22/HSP27 (the third day after PCI) have synergistic predictive value for MACE after PCI. This innovative dynamic monitoring model addresses the key limitations of traditional static detection approaches, offering clinicians a promising tool for potential risk evaluation and guiding prompt therapeutic intervention in STEMI patients. Its clinical significance lies particularly in enhancing early risk stratification, thereby potentially improving patient outcomes.
No takes yet. Share an insight, caveat, or question.
Hu et al. (2025) conducted a cohort in ST-segment elevation myocardial infarction (STEMI) post-PCI (n=266). Combined dynamic monitoring of IL-6, HSP22, and HSP27 vs. GRACE and TIMI scores was evaluated on Prediction of major adverse cardiovascular events (MACE) at 6 months (AUC 0.875). A combined dynamic monitoring model of IL-6, HSP22, and HSP27 predicted major adverse cardiovascular events within 6 months after emergency PCI in STEMI patients with an AUC of 0.875, outperforming conventional GRACE and TIMI scores.
Synapse has enriched 10 related papers. Consider them for comparative context: